Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) EPS (Basic) (2016 - 2025)

Spyre Therapeutics' EPS (Basic) history spans 11 years, with the latest figure at -$77.78 for Q4 2025.

  • For Q4 2025, EPS (Basic) fell 146.69% year-over-year to -$77.78; the TTM value through Dec 2025 reached -$121.5, up 3.81%, while the annual FY2025 figure was -$79.02, 37.88% up from the prior year.
  • EPS (Basic) reached -$77.78 in Q4 2025 per SYRE's latest filing, down from -$0.15 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $40.14 in Q2 2023 to a low of -$77.78 in Q4 2025.
  • Average EPS (Basic) over 5 years is -$12.51, with a median of -$4.76 recorded in 2022.
  • Peak YoY movement for EPS (Basic): skyrocketed 14966.67% in 2023, then plummeted 5011.63% in 2024.
  • A 5-year view of EPS (Basic) shows it stood at $0.69 in 2021, then crashed by 779.71% to -$4.69 in 2022, then plummeted by 505.76% to -$28.41 in 2023, then decreased by 10.98% to -$31.53 in 2024, then tumbled by 146.69% to -$77.78 in 2025.
  • Per Business Quant, the three most recent readings for SYRE's EPS (Basic) are -$77.78 (Q4 2025), -$0.15 (Q3 2025), and -$19.62 (Q2 2025).